Clinical trial • Phase I|Phase III • Dermatology

latanoprost acid for Androgenetic alopecia

Phase I|Phase III trial of latanoprost acid for Androgenetic alopecia. 24 participants.

Overview

Trial Therapeutic Area
Dermatology
Trial Disease
Androgenetic alopecia
Trial Stage
Phase I|Phase III
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
19-12-2025
First CTIS Authorization Date
29-04-2026

Trial design

Phase I|Phase III trial across 1 site in Poland.

Target Sample Size
24

Eligibility

Recruits 24 No vulnerable populations selected; participants are healthy volunteers; no assent or minor consent details provided..

Vulnerable Population
No vulnerable populations selected; participants are healthy volunteers; no assent or minor consent details provided.

Recruitment

Planned Sample Size
24
Recruitment Window Months
12
Consent Approach
Not specified. Informed consent process not described; participants are adults (healthy volunteers); no assent or language details provided.

Geography

Total Number Of Sites
1
Total Number Of Participants
24

Poland

Earliest CTIS Part Ii Submission Date
16-01-2026
Latest Decision Or Authorization Date
29-04-2026
Processing Time Days
103
Number Of Sites
1
Number Of Participants
24

Sites

Site Name
Mtz Clinical Research Powered By Pratia
Department Name
Clinical Unit
Principal Investigator Name
Piotr Sobieraj
Principal Investigator Email
piotr.sobieraj@pratia.com
Contact Person Name
Piotr Sobieraj
Contact Person Email
piotr.sobieraj@pratia.com
Number Of Participants
24

Sponsor

Primary sponsor

Full Name
Bioresearch Pharma S.A.
Organisation Type
Pharmaceutical company
Country Of Registered Address
Poland

Investigational products

Investigational Product Name
topical product containing latanoprost acid
Active Substance
latanoprost acid
Modality
Small molecule
Routes Of Administration
Topical
Route
Topical

Related trials

Other published trials that may interest you.